朗姿股份(002612.SZ):重要參股公司若羽臣IPO過會
格隆匯7月3日丨朗姿股份(002612.SZ)宣佈,公司近日根據中國證監會網站信息公開顯示,公司重要參股公司若羽臣首次公開發行股票的申請於2020年7月2日獲得中國證監會第十八屆發審委2020年第97次工作會議審核通過。
因若羽臣經營發展需要,引入新的戰略投資者,截止目前,公司持有若羽臣1500萬股股份未變,佔其首次公開發行前總股本的比例變為16.43%。
若公司所持若羽臣股份上市,該股份自若羽臣上市之日起12個月內不得轉讓,該部分投資收益無法估計,對公司未來財務狀況和經營成果的影響程度無法確定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.